Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02254681 · ClinicalTrials.gov registry record · Phase 2
Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC
A Phase 2 study, sponsored by Allina Health System.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02254681 is a Phase 2 study that was terminated before completion, run by Allina Health System. The registered enrollment target is 6 participants.
The verdict
NCT02254681, a Phase 2 study, was terminated before completion, sponsored by Allina Health System.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The overall goal of this study is to determine the safety and efficacy of combination treatment of low-dose fractionated radiation therapy with gemcitabine-cisplatin chemotherapy for locally advanced mass forming intra-hepatic cholangiocarcinoma.
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- RADIATION low dose radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02254681
The ClinicalTrials.gov registry entry for NCT02254681 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allina Health System, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT02254681 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02254681 about?
NCT02254681 is a clinical study titled "Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC". The overall goal of this study is to determine the safety and efficacy of combination treatment of low-dose fractionated radiation therapy with gemcitabine-cisplatin chemotherapy for locally advanced mass forming intra-hepatic cholangiocarcinoma.
What is the current status of trial NCT02254681?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2014-09. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02254681?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), low dose radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT02254681?
This trial is sponsored by Allina Health System, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.